The future of cell therapy: scaling production for global reach
Scaling up cell therapy is no easy feat. PluriCDMO's Andy Lewin reveals the critical factors for success and how they are helping companies bring life-saving therapies to market.
List view / Grid view
Articles
Obesity care gets personalised: tailoring therapies with Phenomix
Find out how Phenomix Sciences is transforming obesity treatment by identifying patient subtypes for more targeted and effective therapies.
Building better brain models for Parkinson’s disease and beyond
Professor Jens Christian Schwamborn is advancing personalised medicine for Parkinson’s disease using patient-specific brain organoids, offering new hope for more effective and targeted treatments.
New therapy shows promise in strengthening CAR-T responses
CAR-T therapy has shown effectiveness in cancer treatment, but relapse often occurs due to limited cell persistence. New strategies aim to improve CAR T-cell durability for longer lasting remission.
Large language models: now more affordable and reliable than ever
In this article, Dr Raminderpal Singh explores the transformative impact of the Deepseek R1 open-source large language model on drug discovery. Its potential offers exciting opportunities for both scientists and software developers, marking a significant advancement for the life sciences community.
Empowering women in STEM: championing change in genetics
An advocate for genetic medicines and the enormous potential they hold, Leah Sabin at Regeneron Genetic Medicines reveals how passion and curiosity can forge the path to a rewarding career in STEM.
Experts explore the future of iPSC-based cell therapies
19 February 2025 | By
Discover the transformative potential of iPSC-based therapies in regenerative medicine, alongside their challenges including scalability, safety and targeted delivery.
Landmark study aims to detect Parkinson’s before symptoms
Grifols' Chronos-PD initiative leverages its extensive plasma repository to identify early biomarkers of Parkinson's disease, advancing early detection and contributing to the development of innovative therapies.
Scientific workflow for hypothesis testing in drug discovery: part 3 of 3
Drug discovery scientists develop and test complex hypotheses using data and expertise, and build workflows to support this. In this third and final article, Dr Raminderpal Singh and Nina Truter summarise the tools used in the scientific workflow – and include key considerations.
Using clinical genomics and AI in drug development to elevate success
How are clinical genomics and AI transforming drug development? Industry experts reveal how these technologies improve target identification, patient stratification, and trial design to drive higher success rates.
New cell therapy model accelerates cancer treatment development
CTMC, a joint venture between Resilience + MD Anderson Cancer Center, is transforming cancer treatment with faster, more efficient cell therapy development - learn how they’re doing it.
New study links type 2 diabetes to accelerated cognitive decline
Study reveals how type 2 diabetes accelerates cognitive decline by damaging white matter in the brain. Sam Hashemi at Prenuvo explains how advanced AI and whole-body MRI technology are opening new possibilities for early intervention.
Promising Alzheimer’s drug earns FDA fast-track designation
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.
Cilta-cel: A new era in multiple myeloma treatment
New cell therapy, Cilta-cel, shows promise in the treatment of multiple myeloma, providing a personalised approach with the potential for long-term remission.
New study explores safer antidepressants for pregnant women
A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.
